Interferon-α Therapy and Anti–Human Leukocyte Antigen Antibodies in Hepatitis C Virus–Positive Patient: Case Report

Cervelli, C.; Fontecchio, G; Fioroni, Maria Aurora; Azzarone, R.; Battistoni, C.; Maccarone, D.; Pisani, F.; Papola, F.

doi:10.1016/j.transproceed.2007.05.013

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In a previous case report, IFN-α treatment resulted in increased percentage PRA levels and development of new specific PRAs, indicating that IFN may mediate changes in immune system responses. 26 The IFN-α-based therapy induces expression of various genes, which include genes involved in antigen presentation and T-cell activation. 27,28 The IFN-stimulated genes related to T-cell activation also are induced during treatment of HCV with IFN-α.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Chronic hepatitis C virus infection compromises hemodialysis patients and increases liver-related mortality. Interferon treatment is associated with improved sustained virological response rates and increased risk of graft loss after kidney transplant. This may be related to the development of antihuman leukocyte antigen antibodies, which may be a surrogate marker of potent immune response. We evaluated panel reactive antibody 1 and 2 levels for prediction of sustained viral response in patients with kidney transplant. Materials and Methods

show abstract

Section: Discussionmentioning

confidence: 99%

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…For patients with end‐stage kidney disease (ESKD) renal transplantation is the preferred form of renal replacement therapy, with improved mortality and quality of life compared to dialysis. Allo‐antibodies against human leukocyte antigen (HLA) are formed by exposure from previous blood transfusions, tissue allografts, pregnancy [1], or rarely cross‐reactivity following infection [2,3] or its treatment [4]. Patients with an elevated panel reactive antibody (PRA) titre are disadvantaged because of difficulty finding an immunologically compatible graft.…”

Section: Introductionmentioning

confidence: 99%

Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks

Rogers

Eng

et al. 2010

Transplant International

View full text Add to dashboard Cite

Summary Desensitization protocols reduce donor‐specific anti‐HLA antibodies (DSA) and enable renal transplantation in patients with a positive complement‐dependent cytotoxic cross‐match (CDC‐CXM). The effect of this treatment on protective antibody and immunoglobulin levels is unknown. Thirteen patients with end‐stage renal disease, DSA and positive CDC‐CXM underwent desensitization. Sera collected pre‐ and post‐transplantation were analysed for anti‐tetanus and anti‐pneumococcal antibodies, total immunoglobulin (Ig) levels and IgG subclasses and were compared to healthy controls and contemporaneous renal transplant recipients treated with standard immunosuppression alone. Ten patients developed negative CDC‐CXM and enzyme‐linked immunosorbent assay (ELISA) and underwent successful transplantation. Eight recipients achieved good graft function without antibody‐mediated or late rejection, BK virus or cytomegalovirus infection. One patient had primary non‐function due to recurrent oxalosis, and one patient with immediate graft function died from septicaemia. Seven recipients required post‐operative transfusion and three developed septicaemia. DSA remained negative by ELISA at 12 months, but were detectable by Luminex®. Anti‐tetanus and anti‐pneumococcal antibodies, total Ig and IgG subclasses were below the normal range but comparable to levels in renal transplant recipients who had not undergone desensitization. Desensitization protocols effectively reduce DSA and allow successful transplantation. Post‐operative bleeding and short‐term infectious risk is increased. Protective antibody and serum immunoglobulin levels are relatively preserved.

show abstract